ALTITUDE PHARMA, INC.

Medtech

inhaled proton pump inhibitor formulation for pulmonary fibrosis treatment

Grants
$150K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Inhaled PPI for Treatment of Pulmonary Fibrosis$149,950
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
757Cell And Molecular Tissue Engineering LLC——
758TENDO TECHNOLOGIES INC——
759SEARCHLIGHT SENSORS——
760ALTITUDE PHARMA, INC.——
761BIOSENIX LLC——
762GraceFall, Inc.——
763INNOGIZED TECHNOLOGIES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.